Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestogen presented as a 13.5 mg intrauterine system for intrauterine use. It provides continuous local release of levonorgestrel to prevent pregnancy, offering a convenient, reversible contraceptive option for women of reproductive age. The device remains effective for up to three years, reducing the need for frequent medical visits.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled delivery of this EU‑approved contraceptive device and supporting regulatory compliance across regions.

Jaydess, a levonorgestrel intrauterine system, is used within the contraceptive pathway to prevent unintended pregnancy.

Contraception (prevention of pregnancy): provides highly effective, long‑acting reversible contraception for up to three years in women of reproductive age. Post‑partum contraception: offers a hormone‑based intrauterine option for women after childbirth who desire reliable birth control. Breastfeeding contraception: suitable for lactating women seeking a non‑systemic method that does not affect milk production.

Levonorgestrel intrauterine systems may be associated with a range of adverse events, which are categorized by frequency and severity.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or cramping pain after insertion - Breast tenderness - Headache - Acne or oily skin

Serious or Rare Side Effects: - Uterine perforation during or after insertion - Expulsion of the device - Pelvic inflammatory disease or infection - Ectopic pregnancy if contraception fails - Severe allergic reaction (anaphylaxis) - Deep vein thrombosis (rare)

Before prescribing Jaydess, clinicians should consider several precautionary measures to ensure patient safety.

Screen for contraindications: verify absence of active pelvic infection, pregnancy, or uterine anomalies. Assess bleeding risk: counsel patients about possible changes in menstrual patterns. Monitor for device displacement: schedule follow‑up examinations to detect expulsion or malposition. Consider hormonal sensitivity: discuss potential mood changes or breast tenderness. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from an intrauterine system can interact with other medicines, affecting contraceptive efficacy or safety.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may lower levonorgestrel levels. - Rifampicin or other strong CYP3A4 inducers: can reduce contraceptive effectiveness. - Antiretroviral drugs (e.g., efavirenz): may decrease hormone exposure. - St John’s wort: herbal inducer that may compromise efficacy.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., ampicillin): unlikely to affect IUS but monitor for bleeding changes. - Antifungal agents (e.g., ketoconazole): may modestly increase hormone levels. - Hormonal therapies (e.g., estrogen patches): assess additive hormonal effects.